Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?
British journal of pharmacology July 28, 2025 Omar Qureshi, Jamie Cowley, Ashley Pegg et al. 5 citations
Psychedelic drugs that activate 5-HT2A receptors are known for treating psychiatric disorders, but growing evidence shows they also modulate immune responses by inhibiting pro-inflammatory cytokine release. In vivo studies demonstrate that psychedelics like (R)-DOI reduce inflammation in animal models of asthma and other inflammatory diseases. Clinical studies with psilocybin show effects on circulating cytokine levels, supporting translation from animal models to humans. These findings highlight the promise of targeting inflammation therapeutically. Recent research has identified compounds that maintain therapeutic potential without causing psychedelic effects, termed PIPI drugs (Psychedelic drug Informed but Psychedelic experience Inactive), offering new avenues for treating mental health and inflammation.